Seralutinib is an inhaled PDGFR inhibitor for pulmonary arterial hypertension research
**Background** Pulmonary arterial hypertension (PAH) is a severe progressive disease characterized by the remodeling of small pulmonary arteries, leading to increased pulmonary vascular resistance and right heart failure. A key…